Renowned Investment Bank Reiterates Buy Rating For Israeli Medical Company
HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target: A Deep Dive into the Potential of $BLRX.
BioLine Rx (NASDAQ: $BLRX), an Israeli biopharmaceutical development company, recently received a reiterated buy rating from the renowned investment bank, HC Wainwright & Co. The financial institution has maintained a price target of $21 for BioLine Rx, indicating a positive outlook for the company's future. $BioLine Rx(BLRX.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
